Nemesis Bioscience Closes Funding Round And Begins Preclinical Programmes
Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total...
read moreA key part of our value in economic terms is in the pivotal early role we play in getting technology companies off the ground, often whilst they are still in the laboratory and before they are ready to spin out. Many of our companies might never have made it, if it had not been for our support and the technologies and services they offer would not have progressed beyond an interesting concept.
We invest at the very earliest stage and many of our companies are still very much in development mode, meaning that the larger numbers in terms of sales, jobs and taxes are still to come as the companies mature.
Looking forward is of course a hazardous enterprise, and several of our companies are bound to fail at some point. But we like to think that we can be confident that the growth we have seen to date will be sustained and that we will see more highly skilled jobs, more exports and higher levels of wider impact in terms of the supply chain and the wider economy. And, eventually, more successful realisations of Rainbow investments so that we can recycle the money into future generations of outstanding UK technologies.
Current as at: 31st January 2016
Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total...
read moreBritish molecular diagnostics company Cytox plans to make a molecular test for the early-stage...
read more